IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Applicant:

Yair FELD et al

Serial No.:

09/691,889

Filed:

October 20, 2000

For:

NUCLEIC ACID CONSTRUCTS AND CELLS, AND

METHODS UTILIZING SAME FOR MODIFYING THE ELECTROCHEMICAL CONDUCTANCE OF

EXCITABLE TISSUES

Examiner:

FALK, ANNE MARIE

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dated: July 27, 2006

Group Art Unit: 1632

Attorney

Docket: 00/20989

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Enclosed is a PTO Form 1449 which lists citations which may be material to the patentability and examination of the above identified application. Also enclosed are copies of the references cited. These are submitted in compliance with the duty of disclosure defined in 37 CFR 1.56. The Examiner is requested to make these citations of official record in this application.

This Supplemental Information Disclosure Statement is being filed subsequent to an Office Action being mailed and a late fee of \$180 is due. Please charge my Deposit Account 50-1407 for this fee, as well as any additional fees due.

This Supplemental Information Disclosure Statement under 37 CFR 1.56 is not to be construed as a representation that a search has been made, that additional matter which is material to the examination of this application does not exist, or that any or more of these citations constitutes prior art.

Respectfully submitted,

Martin D. Moynihan

Registration No. 40,338

08/04/2006 SDENBOB1 00000010 501407 03691889

Kartin a Moyuchan

01 FC:1806

180.00 DA

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S.Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERC Under the Paperwork Reduction Act of 1995, no person point to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO					Complete if Known				
					Application Number	09/691,889			
SUPPLEMENTAL					Filing Date	October 20, 2000			
INFORMATION DISCLOSURE					First Named Inventor	Yair FELD et al			
STATEMENT BY APPLICANT					Art Unit	1632			
(use as many sheets as necessary)					Examiner Name FALK, ANNE MARIE				
Sheet	Sheet 1		of	2	Attorney Docket Number	00/20989			
U.S. PATENT DOCUMENTS									
Examiner Initials*	Cite No. ¹	Document Number		ation Date D-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear			
	1	Number-Kind Code ^{2 (if known)} US-6,110,459	08-29-2	000	Mickle et al.				
	2	US-6,099,832	08-8-2000		Mickle et al.				
	-	03-0,033,832	08-8-20		whickle et al.				
	ļ .								
	ļ								
1	L								

FOREIGN PATENT DOCUMENTS									
Examiner Initials*	Cite No. 1	Foreign Patent Documents Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document		Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ₆		
	-								
Examiner Signature			I		Date Considered		I I		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-003

09/691.889

Complete if Known

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERC ond to a collection of information unless it contains a valid OMB control number. Under the Paperwork Reduction Act of 1995, no person

Application Number

				Application Number	02/021,002			
SUPPLEMENTAL			Filing Date	October 20,	October 20, 2000			
				First Named Inventor Yair FEL		et al		
Ţ	NFOR	MATION DISCLOSURE	Group Art Unit 1632					
5	STATE	MENT BY APPLICANT	Examiner Name	iner Name FALK, ANNE				
	(use	as many sheets as necessary)						
Sheet	2		2	Attorney Docket Number	00/20989			
		OTHER PRIOR ART – NON PA	TEN	T LITERATURE DOCUME	NTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.						
	3	Ebihara et al. "Co-Expression of Lens Fiber Connexins Modifies Hemi-Gap- Junctional Channel Behavior", Biophysical Journal, 76: 198-206, 1999.						
	4	Grosshans "Gene Therapy - When A Simple Concept Meets A Complex Reality. Review on Gene Therapy", Functional and Integrative Genomics, 1: 142-145, 2000.						
	5	Gage "Cell Therapy", Nature, 392(Suppl.): 18-24, 1998.						
	6	Race et al. "Muscle Regeneration of Injured Myocardium", Journal of Cellular Biochemistry, Suppl. 150: 73, 1991. Abstract.						
	7	Race et al. "Satellite Cells for Myocardial Regeneration", Physiologost., 32: 220, 1989. Abstract.						
	8	Marelli et al. "Satellite Cell Implantation for Neo-Myocardial Regeneration", First International Congress of the Cell Transplanty Society, 1(2/3), 1992. Abstract.						
	9	Murry et al. "Skeletal Myoblast Transplantation for Repair of Myocardial Necrosis", Journal of Clinical Investment, 98(11): 2512-2523, 1996.						
	10	Chiu et al. "Cellular Cardiomyoplasty: Myocardial Regeneration With Satellite Cell Implantaion", Annual Meeting of the Thoraxic Surgeons, 60:12-18, 1995.						
	11	Koh et al. "Differentiation and Long-Te Heart", Journal of Clinical Investigation	rm S	urvival of C2C12 Myoblast C				

Li et al. "Human Pediatric and Adult Ventricular Cardiomyocytes in Culture:

Li et al. "Cardiomyocyte Transplantation Improves Heart Function", Annual

Myocardium", Journal of Tissue Culture Methods, 14: 92-100, 1992. Thompson "Fetal Transplants Show Promise", Science, 257: 868-870, 1992.

Leor et al. "Transplantation of Fetal Myocardial Tissue Into the Infarcted

Meeting of Thoraxic Surgeons, 62: 654-661, 1996.

Transplants, 94(9 Suppl.II): 332-336, 1996.

Circulation Research, 78(2): 283-288, 1996.

Assessment of Phenotypic Changes With Passaging", Cardiovascular Research, 32:

Li et al. "Method of Culturing Cardiomyocytes From Human Pediatric Ventricular

Myocardium of Rat - A Potential Method for Repair of Infarcted Myocardium?", Cell

Signature	Considered	

Li et al. "In Vivo Survival and Function of Transplanted Rat Cardiomyocytes",

362-373, 1996.

12

13

14

15

16

17

Substitute for form 1449A/PTO

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

considered. Include copy of this form with next communication to applicant.

1. Applicant's unique citation designation number (optional).

2. Applicant's unique citation designation number (optional).

3. Applicant's unique citation designation number (optional).

4. Applicant's unique citation designation number (optional).

5. Applicant's unique citation designation number (optional).

6. Applicant's unique citation designation number (optional).

7. Applicant's unique citation designation number (optional).

7. Applicant's unique citation designation number (optional).

8. Applicant's unique citation designation number (optional).

8. Applicant's unique citation designation number (optional).

9. Applicant is unique citation designation number (optional).

9. Applicant gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.